Andrew Oxtoby - Apr 10, 2025 Form 4 Insider Report for Kalaris Therapeutics, Inc. (KLRS)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KLRS	Stock Option (Right to Buy)	Award	$0	+287K		$0.00	287K	Apr 10, 2025	Common Stock	287K	$7.31	Direct	F1

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

President and Chief Executive Officer